CME/CE-Accredited Daily Summaries

IAS 2007: Day Three & Conference Roundup
Joel Gallant, M.D., M.P.H., wraps up our daily recap series with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.

• Read transcript
• Listen to audio with slides (no downloading necessary)
• Audio only (MP3 podcast)   (10MB, 24 min.)
• Read CME/CE activity information

IAS 2007: Day Two
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.

• Read transcript
• Listen to audio with slides (no downloading necessary)
• Audio only (MP3 podcast)   (10MB, 24 min.)
• Read CME/CE activity information

IAS 2007: Day One
Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.

• Read transcript
• Listen to audio with slides (no downloading necessary)
• Audio only (MP3 podcast)   (10MB, 24 min.)
• Read CME/CE activity information

• Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
  Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Late Breaker Track B: Clinical Treatment and Care Track (July 25, 2007)
  From Kaisernetwork.org
  
  
• Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Maraviroc Update: An IAS 2007 Summary (July 25, 2007)
  Two interesting subanalyses of the maraviroc studies MOTIVATE 1 and 2 show two things: One demonstrates the benefit of including a potent new drug as part of an OBR when initiating treatment in patients with significant resistance. The second subanalysis showed a trend toward higher rates of virologic suppression with twice-daily maraviroc compared to maraviroc once daily. Edwin DeJesus, M.D., reports from IAS.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Clinical Trials on Investigational Antiretrovirals (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Faster Viral Decay With Raltegravir (July 24, 2007)
  Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Research on Prevention and Treatment: The Prospects for RNA Interference, Next Steps on Male Circumcision and Novel Treatments on the Horizon (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  

• Blood Test Predicts Dangerous Reaction to Abacavir (July 27, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• HIV Patients Likely to Get Potentially Fatal Brain Diseases (July 26, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• HIV Patients Live Longer, Face Greater Risks (July 26, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Can HLA-B*5701 Testing Help Avoid Abacavir Hypersensitivity Reaction? (July 25, 2007)
  Avoiding abacavir hypersensitivity reaction may be as easy as screening for the HLA-B*5701 allele in any HIV-infected, abacavir-naive patient for whom abacavir therapy is being considered. Graeme Moyle, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Rate of OIs and Death Significantly Higher in HIV/HBV- or HIV/HCV-Coinfected Patients (July 25, 2007)
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Tenofovir-Containing Regimens May Not Be the Best Option for Patients With Abnormal Baseline Renal Function (July 25, 2007)
  Tenofovir-containing regimens may not be the best option for patients who already have an abnormal baseline renal function; however, for patients with an otherwise normal baseline renal function, who are not taking nephrotoxic agents or who do not have significant comorbid conditions that predispose them to renal insufficiency, routine renal monitoring, as we do for many other patients, should suffice before prescribing tenofovir.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• HIV/TB: An Evolving Epidemic (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Insight Into the Burden of Coronary Artery Disease in HIV-Infected Patients (July 24, 2007)
  This is the first moderately sized study to examine at a histological level the lesions associated with the increased risk of myocardial infarction among HIV-infected individuals that has been reported in multiple case series and cohort studies. Margaret Hoffman-Terry, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
  NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Hepatitis Co-Infection -- Not as Easy as A,B,C (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• TB/HIV: Still a Deadly Partnership (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Treatment Strategies for Patients Coinfected with Hepatitis B and C (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• HIV/TB Co-infection: Meeting the Challenge (July 22, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  

• Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
  It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
  With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  

• ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
  Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment (July 25, 2007)
  For the first time, a drug has been found that matches the potency of lopinavir/ritonavir in second-line and third-line patients, and which might potentially even outperform lopinavir/ritonavir in certain numbers of those patients. All without compromising safety and tolerability, and apparently without paying resistance consequences if virologic failure occurs. Edwin DeJesus, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Switching to Thymidine-Sparing Regimens Successful (July 25, 2007)
  Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• New Research on Pediatric HIV Infection (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Treatment of Early HIV Disease (July 23, 2007)
  From Kaisernetwork.org
  
  

• Australia: One-Third of HIV Sufferers Going Hungry, Study Says (July 24, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Global Financing of HIV Prevention, Treatment, Care and Research (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Australia: World on Cusp of Beating AIDS Says Expert (July 23, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  

• Plenary: The HIV/Life Cycle: Understanding HIV Pathogenesis, Accelerating ARV Rollout and Exploring the Clinical Implications of Ageing (July 23, 2007)
  From Kaisernetwork.org
  
  
• The HIV/Life Cycle: Understanding HIV Pathogenesis, Antiretroviral Rollout and the Clinical Implications of Ageing (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  

• Treating HIV-Infected Infants Early Helps Them Live Longer (July 27, 2007)
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• Only 15% of HIV-Positive Children Globally Have Access to HIV Meds (July 25, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• Pediatric HIV Infection -- What's New? (July 24, 2007)
  From Kaisernetwork.org
  
  

• Microbicide Candidate Ushercell Not Effective in Preventing HIV (July 27, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Microbicides and Mucosal Immunity (July 25, 2007)
  From Kaisernetwork.org
  
  
• Australia: Global Effort to Prevent HIV in Male-to-Male Sex Launched (July 24, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Australia: Lemons Fail Acid Test in HIV War (July 24, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Female-Initiated HIV Prevention Techniques (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Increasing Access to HIV Testing and Protecting Human Rights (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Male Circumcision, New Antiretrovirals, Genetic Engineering Most Promising HIV Prevention, Treatment Methods, Conference Delegates Say (July 24, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• Research on Prevention and Treatment: The Prospects for RNA Interference, Next Steps on Male Circumcision and Novel Treatments on the Horizon (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Prophylactic HIV Vaccines: Where Are We? (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Access to Care in the Context of HIV Vaccine and Other Prevention Trials: Setting Standards and Making it Happen Through Participation (July 22, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Are We Prepared for PrEP? The Challenges of Implementing Proven Biomedical Prevention Technologies (July 22, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Kevin De Cock Discusses International HIV Testing Guidelines and Male Circumcision (July 22, 2007)
  De Cock is the director of HIV/AIDS at the World Health Organization.
  From Kaisernetwork.org
  
  
• 4th International AIDS Society Conference Set to Begin in Australia (July 20, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  

• Australia: Despite Progress, World Still Failing HIV Carriers, Says AIDS Chief (July 23, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Australia: Research on AIDS-Affected Women Neglected, Activists Say (July 23, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• World Must Act to Achieve Commitments to Provide Universal Access to HIV/AIDS Treatment, Conference Delegates Say (July 23, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  

• New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
  In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Prevention of Mother-to-Child Transmission of HIV (July 24, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  

• HIV Testing -- Increasing Access, Increasing Uptake, and Protecting Human Rights (July 24, 2007)
  From Kaisernetwork.org
  
  
• Australian Minister Announces $400 Million to Fight AIDS (July 23, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Emerging Challenges in Designing Prevention Research (July 23, 2007)
  Available as a Webcast, podcast and transcript.
  From Kaisernetwork.org
  
  
• Pedro Cahn Discusses the Sydney Declaration and the Need for More HIV Research (July 22, 2007)
  Cahn is the president of the International AIDS Society.
  From Kaisernetwork.org
  
  

• Official Opening Press Conference (July 22, 2007)
  Available as a Webcast and podcast.
  From Kaisernetwork.org
  
  
• Opening Session: Webcast, Podcast and Transcript (July 22, 2007)
  From Kaisernetwork.org
  
  

• Craig McClure Previews IAS 2007 Research (July 22, 2007)
  McClure is the executive director of the International AIDS Society.
  From Kaisernetwork.org
  
  
• 4th International AIDS Society Conference Set to Begin in Australia (July 20, 2007)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• "Stop Talking About" a Cure for HIV, Top U.S. HIV Official Says (July 19, 2007)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Exclusive IAS 2007 Preview Podcast With Daniel Berger, M.D. (July 7, 2007)
  In The 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO